Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T98052
|
||||
Former ID |
TTDI02305
|
||||
Target Name |
SLAM family member 7 (SLAMF7) (CS1)
|
||||
Gene Name |
SLAMF7
|
||||
Synonyms |
CD2 subset 1; CD2-like receptor-activating cytotoxic cells; CD319; CRACC; Membrane protein FOAP-12; Novel Ly9; Protein 19A; SLAMF7
|
||||
Target Type |
Clinical Trial
|
||||
Disease | Cancer [ICD9: 140-229; ICD10: C00-C96] | ||||
Multiple myeloma [ICD9: 203; ICD10: C90] | |||||
Function |
Isoform 3 does not mediate any NK cell activation.
|
||||
BioChemical Class |
Immunoglobulin
|
||||
UniProt ID | |||||
Sequence |
MAGSPTCLTLIYILWQLTGSAASGPVKELVGSVGGAVTFPLKSKVKQVDSIVWTFNTTPL
VTIQPEGGTIIVTQNRNRERVDFPDGGYSLKLSKLKKNDSGIYYVGIYSSSLQQPSTQEY VLHVYEHLSKPKVTMGLQSNKNGTCVTNLTCCMEHGEEDVIYTWKALGQAANESHNGSIL PISWRWGESDMTFICVARNPVSRNFSSPILARKLCEGAADDPDSSMVLLCLLLVPLLLSL FVLGLFLWFLKRERQEEYIEEKKRVDICRETPNICPHSGENTEYDTIPHTNRTILKEDPA NTVYSTVEIPKKMENPHSLLTMPDTPRLFAYENVI |
||||
Drugs and Mode of Action | |||||
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
TEP | EXP Info | ||||
References | |||||
Ref 523429 | ClinicalTrials.gov (NCT01335399) Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma. U.S. National Institutesof Health. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.